Technology
Health
Medical

Helius Medical

$6.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (0.74%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Helius Medical and other stocks, options, ETFs, and crypto commission-free!

About

Helius Medical Technologies, Inc. operates as a medical technology company, which engages in the development of products for the treatment of neurological symptoms caused by disease and trauma. It focuses on licensing and acquiring platform technologies that amplify the brain's ability to heal itself. Read More The company was founded in 2014 and is headquartered in Newtown, PA.

Employees
25
Headquarters
Newtown, Pennsylvania
Founded
2014
Market Cap
175.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
71.75K
High Today
$7.00
Low Today
$6.59
Open Price
$6.85
Volume
12.76K
52 Week High
$13.20
52 Week Low
$6.20

Collections

Technology
Health
Medical
2018 IPO
US
North America

News

Simply Wall StMar 18

Helius Medical Technologies, Inc. (NASDAQ:HSDT): Immense Growth Potential?

The most recent earnings announcement Helius Medical Technologies, Inc.’s (NASDAQ:HSDT) released in December 2018 showed that losses became smaller relative to the prior year’s level – great news for investors Investors may find it useful to understand how market analysts predict Helius Medical Technologies’s earnings growth outlook over the next couple of years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better un...

2
MarketWatchMar 6

Helius Medical Technologies Inc.

The global neurostimulation device market which was worth $XX million in 2018 is anticipated to grow at a CAGR of 10.01% during the forecast period of 2019-2027 Helius Medical Technologies, Inc. Provides Update on FDA's Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS(TM) Device SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact th...

34
Markets InsiderMar 6

Helius Medical Technologies, Inc. to Present at Oppenheimer’s 29th Annual Healthcare Conference

NEWTOWN, Pa., March 06, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in Oppenheimer’s 29th Annual Healthcare Conference at the Westin New York Grand Central in New York, New York. Management will present on Wednesday, March 20 at 2:10 p.m. Eastern Time. A live audio webcast of the conference presentation will be provided under the ‘Event...

13

Earnings

-$0.22
-$0.21
-$0.20
-$0.19
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.22 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.